Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer by Mathis, S. et al.
Horizon Scanning in 
Oncology 
Eribulin (Halaven®) as third- or 
late- line mono-therapy for 
advanced/metastatic breast cancer 
 
 
 
DSD: Horizon Scanning in Oncology Nr. 018
ISSN online 2076-5940

Horizon Scanning in 
Oncology 
Eribulin (Halaven®) as third- or 
late- line mono-therapy for 
advanced/metastatic breast cancer 
 
 
 
Vienna, June 2011 
 
 Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft in collaboration with Agencja Oceny Technoligii Me-
dycznych, (AOTM;Poland) 
Azienda Ospedaliera Universitaria Integrata Verona (UVEF; Italy) 
Project leader: Dr. Anna Nachtnebel, MSc 
Author(s):  DI Dr. Stefan Mathis-Edenhofer    (LBI-HTA) 
    Tomasz Garbaty, MSc Eng    (AHTAPol) 
   Jadwiga Czeczot, MSc Pharm    (AHTAPol) 
   Dr.ssa Paola Rosa Maran    (UVEF) 
   Dr.ssa Chiara Alberti    (UVEF) 
Internal review:  Dr. Anna Nachtnebel, MSc 
 
External review: Prof. Dr. Martin Pecherstorfer 
   Head of Haemtalogic-Oncologic Service, 
   Landesklinikum Krems, Austria 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research 
and on a limited literature search. It is not a definitive statement on safety, effec-
tiveness or efficacy and cannot replace professional medical advice nor should it be 
used for commercial purposes. 
This product of collaboration with AOTM and AOUIV is an offspring of the Euro-
pean network for Health Technology Assessment (EUnetHTA) Project that was sup-
ported by a grant from the European Commission. The sole responsibility lies with 
the author(s), and the Commission is not responsible for any use that may be made 
of the information contained therein. 
 
CONTACT INFORMATION
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nussdorferstr. 64, 6 Stock, A-1090 Vienna 
http://www.lbg.ac.at/de/lbg/impressum 
Responsible for Contents: 
Ludwig Boltzmann Institute of Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicize 
the research results of the Ludwig Boltzmann Institute of Health Technology Assessments. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at 
“http://eprints.hta.lbg.ac.at”: 
DSD: Horizon Scanning in Oncology Nr. 018 
ISSN online 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/dsd.html 
© 2011 LBI-HTA – All rights reserved
LBI HTA | 2011 3 
1 Drug description 
Generic/Brand name/ATC code:  
Eribulin Mesylate (Eribulin), E7389/Halaven®/L01XX41 
Developer/Company: 
Eisai Europe Ltd.  
Description:  
Eribulin is a synthetic macrocyclic ketone analogue of halichondrin B,  
which is naturally found in marine sponges [1]. Eribulin stops the formation 
of mitotic microtubule spindles by binding to tubulin proteins [2]. Accord-
ingly, eribulin blocks mitosis by disrupting the mitotic spindle system, lead-
ing to an incomplete mitosis cycle and consequently to cell death [1].  
In general, all cytotoxic drugs (like eribulin) act on heavily proliferating 
cells (i.e. performing many mitoses). Therefore, cytotoxic drugs foremost act 
on neoplasms’ because tumour cells are usually proliferating heavily and are 
therefore targeted by the drug. On the other hand, common side effects are 
also induced in healthy tissue with strong proliferation (like bone marrow) 
by the same mechanism.  
2 ml vials of Halaven®, containing 0.88 ml eribulin are available. The dosing 
is based on the patient’s body surface area with a recommended dose of 1.23 
mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) at day 1 and day 8 of a 
21-day cycle [3]. 
Eribulin is administered intravenously (i.v.) within 2-5 minutes. The ad-
ministration should be performed with the necessary precautions regarding 
cytotoxic medical products [3]. 
2 Indication 
Eribulin is indicated for locally advanced or metastatic breast cancer (BC) as 
a 3rd-line mono-therapy.  
3 Current regulatory status 
The EMA approved Halaven®  “for  the  treatment  of  patients  with  locally  
advanced  or  metastatic BC who have progressed after at least two chemo-
therapeutic regimens  for  advanced  disease” in March 2011. Prior  therapy  
eribulin blocks mitosis 
by targeting the mitotic 
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effect on tumour cells 
based on their 
proliferation speed 
single dose: 1.23 mg/m2 
eribulin 
i.v. application 
3rd-line drug for 
advanced BC 
indication in EMA 
approval citation  
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should  have  included  an  anthracycline and a taxane unless patients were 
not suitable for these treatments” [3]. 
Eribulin was approved by the FDA in November 2010 for “the treatment of 
patients with metastatic BC who have previously received at least two che-
motherapeutic regimens for the treatment of metastatic disease. Prior ther-
apy should have included an anthracycline and a taxane in either the adju-
vant or metastatic setting” [4]. 
Additionally, it is approved in Singapore [6] and in Japan [7] and market 
applications have been filed in Switzerland and Canada [6]. 
4 Burden of disease 
In 2008, 4,570 women were newly diagnosed with BC and 1,500 died from 
BC in Austria [5]. Risk factors associated with the development of BC are 
age, positive family history, nulliparity, early menarche or genetic factors. 
The majority of women, that is about 80% , are diagnosed aged ≥ 50 years 
[6] and most breast cancer deaths appear in the 75-84 years-group (~28%). 
In the 65-74 years group, the 55-64 years-group and 85+years-group, the 
death rate is about 20% each. In younger women (45-54 years), death rates of 
10% were recorded [6]. 
The age standardised (WHO World 2001) death rate (per 100,000 popula-
tion) in women with invasive BC declined in the last ten years from 12.4 
(1998) to 9.4 (2008) in Austria [6]. The age standardised incidence rate also 
dropped from 41.1 (1998) to 34.9 (2008) [6].  
Cigler et al. [7] cite that about 20% of women with early stage BC develop 
metastases within 5 years; up to 10% present initially with metastatic dis-
ease. In Austria, about 5% of patients with initially diagnosed BC had dis-
seminated disease [8]. Cure of metastatic BC and complete remissions after 
chemotherapy are rare, resulting in a median survival of about 18 to 24 
months [7]. Only 5 -10% of women survive five or more years [6]. Assuming 
that 10% of women with breast cancer (the prevalence was 54,418 in 2007 in 
Austria [9]) are suffering from advanced/metastatic BC and need late line 
therapy would result in 5,542 women per year. 
The Tumour Node Metastasis (TNM) staging classification is used to de-
termine the disease stage. Besides the staging of the primary tumour, the ex-
tent to which regional lymph nodes are involved and the absence or presence 
of distant metastases are taken into account, leading to four main stage 
groupings (stage I to IV) where metastatic BC is coded as stage IV, advanced 
BC as stage III [10]. Metastases are most common in the bones, liver or the 
lungs and cause, depending on the localisation, local symptoms. Most com-
mon are bone metastases leading to bone pain and pathologic fractures. 
Brain metastases can lead to imbalance, confusion, headache or local weak-
ness or numbness [13]. 
Prognostic factors for metastatic disease include the length of the relapse-
free interval after the initial treatment, the number of metastases, locations 
involved (worse prognosis with hepatic, lymphangitic pulmonary metasta-
ses, bone marrow replacement, carcinomatous meningitis) and biological 
indication in FDA 
approval citation  
approved in the US, 
Singapore, the EU and 
in Japan 
incidence and age 
distribution in Austria 
mortality and age 
distribution in Austria 
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markers (e.g., good prognosis is associated with hormone receptor (HR) 
positive state). Additionally, weight loss, poor performance status and age 
less than 35 years in woman with early stage BC have an  unfavourable 
prognosis [11]. 
Biological markers for prognosis as well as for therapeutic decisions include 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2) status.  
5 Current treatment 
The indication for eribulin, as defined by the EMA, is metastatic BC or lo-
cally advanced BC that has progressed after at least two chemotherapeutic 
regimens given for advanced disease.  
In cases when the disease has progressed to advanced disease, the aim of the 
therapy is palliative. Treatment goals are then to prolong life, to improve 
quality of life (QoL) and to palliate symptoms.  
While the primary strategy for metastatic BC is the administration of sys-
temic therapy, options for locally advanced BC are, additional, surgery and 
radiation. Systemic therapy might thus be delivered as adjuvant, neo-
adjuvant therapy as monotherapy or in combinations. Details of the treat-
ment of advanced BC have been described in a recent Horizon Scanning 
Document on lapatinib [12]. 
Treatment of metastatic BC 
The treatment of metastatic BC should be tailored individually according to 
the tumour biology, locations, receptor status and patient dependent factors 
(tumour symptom burden, “accumulated” toxicity, resistance to former 
therapies, patient preferences). It can be divided into “early-” line therapies 
(first-line, second-line) and late-line (third-line or later-line) therapies. 
First- and second- (early-) line therapeutic options in metastatic BC 
 Chemotherapy 
In advanced disease anthracycline or taxane are accepted as the most effec-
tive drugs in metastatic BC. Chemotherapy with anthracycline or taxane 
should therefore be administered as first-line and second-line therapeutics 
except in patients that could benefit from endocrine (HR positive) or com-
bined therapy (see below).  For deciding if an anthracycline or a taxane 
should be given initially, prior exposure to these drugs and particular side 
effect patterns need to be considered. 
Other agents such as capecitabine, gemcitabine, vinorelbine or etoposide 
which are also independent of the receptor status can be considered as alter-
natives for early-line therapy in patients with a contraindication to anthra-
cyclines or taxanes [13]. 
 Endocrine therapy 
In patients with HR positive metastatic BC and a less aggressive phenotype 
of cancer, the treatment of advanced disease should start with endocrine 
therapy, followed by a second-line endocrine strategy. In contrast, patients 
with positive HR status and an aggressive phenotype, should nevertheless 
biological markers 
eribulin indicated in 
advanced BC 
palliative treatment 
goal 
systemic therapy in 
metastatic BC 
individually tailored 
approach 
anthracycline or taxane 
alternatives 
alternatives to 
anthracycline or taxane  
in HR positive patients 
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receive chemotherapy followed by a second-line maintenance endocrine 
therapy. If the phenotype has changed to a more aggressive form after initial 
hormone therapy, second-line chemotherapy is indicated subsequently [11]. 
 Combination therapy 
In human epidermal growth factor receptor 2 (HER2) positive patients, 
HER2-directed therapies can be used either in combination with chemo-
therapy or endocrine therapy [13]. 
A combined chemotherapy regimen is also an option in the first-line setting. 
This combination (with a stronger tumour effect but also higher toxicity 
compared with sequential administration) can be offered to patients that 
need immediate relief of severe tumour-related symptoms [14]. 
 Other treatment strategies 
While systemic therapy is usually the main therapeutic strand, additional 
local approaches may be indicated. E.g. surgery and/or radiation may be ap-
plied in patients with limited systemic metastases. 
Late-line therapy in metastatic BC 
Little guidance exists for the optimal late-line strategy. Receptor status, pre-
vious exposure to cancer drugs and patient aspects (“cumulated toxicity”) 
may determine the strategy. Substantial evidence gaps exist – for example – 
how third- or later-line therapies compare with best supportive care [11]. 
Options of third-line or later line therapy include vinca alkaloids, gemcit-
abine, capecitapine, ixabepilone (commentary: that is not an alternative 
treatment in all European countries, only in France) and paclitaxel [15]. 
Beside systemic therapy regimes, palliation can be achieved by radiation of 
metastases, osteoclast inhibition for bone metastases and pain medication. 
Treatment of recurrent local-regional BC 
Local recurrences should be considered for further local treatment. As there 
is a risk that metastases might develop, systemic therapy should also be ap-
plied. The evidence for patients in this situation is limited [16].  
6 Evidence 
A systematic literature search in medical databases (Medline, Embase, 
CRD) in addition to a hand search resulted after removal of duplicates in 54 
records overall. Of those, 3 records were included:  2 phase II trials [15, 17] 
and 1 phase III trial [18].  
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Table 1 Summary of efficacy 
Study title: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic BC (EMBRACE) 
Study  
identifier 
ClinicalTrial.gov: NCT00388726;  E7389-G000-305; EudraCT Number: 2006-001949-34 
Randomised (2:1 ratio), two-arm open-label multi centre study; N = 762 [18] 
allocation randomly to 2 treatment groups (508  eribulin, 254 TPC); stratification on geographical 
region, previous capecitabine  treatment and HER2 status 
Design 
Duration  Enrolment: Nov, 2006 - Nov 2008 
Median follow-up: 
The Duration was estimated to be 26.5 month with 630 patients enrolled (to 
reach the target number of 411 events (deaths)) [19] 
First Cut-off: 12 May 2009 [20] 
Data Cut-off: 3 March 2010 [20] 
ITT Analysis 
Hypothesis Superiority of OS 
Intervention 1.4 mg/m2 eribulin mesylate (=1.23 mg/m2 eribulin) iv. during 2 -5 
min on day 1 and day 8 of a 21-day cycle 
Treatment 
groups 
Control Treatment of physician’s choice (TPC), 
defined as any single-agent chemotherapy or hormonal or biological 
treatment approved for the treatment of cancer and to be adminis-
tered according to local practice; radiotherapy; or symptomatic 
treatment alone); 
Among patients who actually received TPC (n=247):  
25% vinorelbine, 19% gemcitabine, 18% capecitabine, 15% taxanes, 
10% anthracyclines, 10% other chemotherapies, 4% hormonal ther-
apy 
Overall survival  
(primary endpoint) 
OS Date of randomisation to death or to last date known alive (cen-
sored) 
Progression-free sur-
vival 
(secondary end-
point) 
PFS From randomisation to the earliest date of disease progression or 
death (from any cause), or censored (as for overall survival) [18] 
Tumour response 
(other reported ou-
come)  
CR, PR, 
SD, PD 
Complete response, partial response, stable disease, progressive dis-
ease 
Tumour response was assessed with Response Evaluation Criteria in 
Solid Tumours (RECIST)[21] ) every 8 weeks (within 1 week), or 
sooner if disease progression was suspected (“Complete or partial 
responses needed confirmation 4 weeks or more later.”). 
Clinical benefit rate 
(other reported ou-
come) 
CBR Duration of complete or partial response or stable disease of at least 
6 months’ duration 
Objective response  
rate  
(Secondary end-
point) 
ORR Complete response or partial response 
Endpoints and 
definitions [18] 
Median duration of 
response 
(other reported ou-
come) 
DoR Time from the first documented response until disease progression, 
death from any cause, or date of censoring 
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Results and analysis 
Analysis  
description 
Primary analysis: 
Overall survival including the intention-to-treat (ITT) population, with a two-sided stratified log-
rank test at a nominal significance level of 0.049 (adjusted for interim analysis) 
Cox regression model to calculate the hazard ratio (HR) 
Characteristics 762 women with locally recurrent or metastatic BC 
 mean age: O/ 55 
ECOG performance status 0, 1, 2: 42%, 49%, 8%; HER2 positive: 16%; 
ER and/or PgR positive: 64%; ER and PgR negative: 25%; 
median number of previous chemotherapy regimes : 4; refractory to 
taxane, capecitabine, anthracycline: 81%, 68%, 58%; previous surgery, 
radiotherapy: 86%, 81%; previous hormone therapy 1x, 2x, 3x, >3x: 
41%, 23%, 11%, 9% 
Inclusion age ≥ 18 ; confirmed BC; between two and five previous chemotherapy 
regimens, including an anthracycline and a taxane, and two or 
more regimens for locally recurrent or metastatic BC; progression 
within 6 months or less of latest chemotherapy; adequate bone mar-
row, liver, and renal function; ECOG performance status of 0–2; and 
life expectancy of 3 months or more 
Analysis  
population 
Exclusion previous participation in an eribulin trial; use of any investigational 
drug within 4 weeks of the study; treatment with chemotherapy, ra-
diation, trastuzumab, or hormone therapy within 3 weeks of the study; 
known brain metastases unless treated and stable; and pre-existing 
neuropathy of grade higher than 2 
Treatment group Eribulin TPC 
Number of subjects 508 254 
OS (months)  
median 
95% CI 
 
13.1 
11.8 - 14.3 
 
10.6 
9.3 – 12.5 
Deaths  
Absolute number (%) 
 
274 (54%) 
 
148 (58%) 
1-year survival rate (%) 53.9 43.7 
Quality of life (QoL) NR NR 
PFS (months) 
median 
95% CI 
 
3.7  
3.3 – 3.9 
 
2.2  
2.1 – 3.4 
Tumour response (abso-
lute number of patients 
( %)) 
CR 
PR 
SD 
PD 
not evaluable 
 
 
 
3 (1%) 
54 (12%) 
208 (44%) 
190 (41%) 
12 (3%) 
 
 
 
0 (0%) 
10 (5%) 
96 (45%) 
105 (49%) 
3 (1%) 
CBR 
95% CI 
106 (23%) 
18.9 – 26.7  
36 (17%) 
12.1 – 22.5 
ORR 
 95% CI 
57/468 (12%) 
9.4 – 15.5 % 
10/214 (5%) 
2.3 – 8.4  
Results 
(Only results of 
the ‘independent 
review’ [18] are 
presented) 
 
 
 
 
 
 
 
DoR (months) 
median 
95% CI 
4.2 
3.8 – 5.0  
6.7  
6.7 – 7.0  
ER ... estrogen receptor; PgR ... progesterone receptor; HR ... hormone receptor HER2 ... human epidermal growth factor receptor 
2;  ECOG ... Eastern Cooperative Oncology Group; CR: complete response; PR: partial response; SD: stable disease; PD: progres-
sion disease; ORR: objective response rate; CBR: clinical benefit rate; DoR: duration of response. 
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Comparison groups  Intervention vs. Control 
HR 0.81 
95% CI 0.66 – 0.99 
OS 
P value 0.041 
HR 0.87 
95% CI 0.71 – 1.05 
PFS 
P value 0.137 
Point estimate NR 
Variability NR 
ORR 
P value 0.002 
Effect estimate per 
comparison 
DoR P value 0.159 
NR ... not reported 
Table 2 Most frequent adverse events (National   Cancer Institute  Common  Terminology  Criteria  for  Adverse 
Events (CTCAE) version 3.0) 
 EMBRACE - NCT00388726  
Grade Outcome (%) Eribulin  
(n= 503) 
TPC (n=247) 
Non-hematologic AEs* 
All Grades Asthenia/fatigue 54 40 
 Peripheral neuropathy 35 16 
 Nausea 35 28 
 Dyspnoea 16 13 
 Bone pain 12 9 
 Mucosal inflammation 9 10 
 Palmar-plantar erythrodysaesthesia 1 14 
Grade 3 or 4 Asthenia/fatigue 9 10 
 Peripheral neuropathy 8 2 
 Nausea 1 2 
 Dyspnoea 4 3 
 Bone pain 2 2 
 Mucosal inflammation 1 2 
 Palmar-plantar erythrodysaesthesia < 1 4 
Grade 4 Asthenia/fatigue 1 0 
 Other AEs  < 1 < 1 
hematologic AEs 
All grades Neutropenia 52 30 
 Leucopenia 23 11 
 Anaemia 19 23 
Grade 3 or 4 Neutropenia 45 21 
 Leucopenia 14 6 
 Anaemia 2 4 
Grade 4 Neutropenia 24 7 
 Leucopenia 2 1 
 Other AEs < 1 < 1 
Grade 5 Treatment-related deaths, absolute number (%) 5 (1%) 2 (1%) 
* AEs with a frequency of 1% or less in either arms within the Grade III or Grade IV category are not displayed here but 
reported in trial publication([18]): By name the not listed AEs are: alopecia, constipation, arthralgia/myalgia, weight loss, 
pyrexia, anorexia, headache, diarrhoea,  vomiting, back pain, cough, pain in extremity 
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In the EMBRACE trial [18], 762 heavily pre-treated (including a taxane and 
an anthracyclin) women with locally recurrent or metastatic BC received ei-
ther eribulin or TPC. Patients had received at least 2 chemotherapies and 
had signs of progressive disease within the last 6 months. Eribulin was as-
signed to 508 patients overall. 254 women were allocated to the control arm 
to receive TPC, which comprised various approved regimens for the third-
line therapy of BC. Agents included were vinorelbine (an anti-tubulin al-
caloid), gemcitabine (nucleotide analogue), capecitabine (orally-
administered pro-drug of 5-flourouracil), taxanes (an anti-tubulin), anthra-
cyclines (cytostatic antibiotic) and other cytotoxic drugs or hormone ther-
apy. To be included, patients had to have an Eastern Cooperative Oncology 
Group performance status of 0–2 and a life expectancy of more than 3 
months.  
At the end of the data cut-off, 274 patients (54%) had died in the eribulin 
group and 148 in the TPC group (58%), median OS was 13.1 in the eribulin 
group and 10.6 in the TPC group. The calculated HR was 0.81 (95% CI: 0.66 
– 0.99; p=0.0041), indicating a significant improvement in overall survival 
(OS) for the eribulin group. 
An exploratory subset analysis according to stratification factors showed a 
significantly longer OS in region 1 (n=488) for eribulin than for TPC (me-
dian 13.1 months [95% CI: 11.8 – 14.9] and 10.1 months [95% CI 8.4 – 10.9], 
respectively) (HR: 0.72; 95% CI 0.57 – 0.92 p=0.009). Region 1 included 488 
patients from North America, Western Europe and Australia, while region 2 
included 193 patients from Eastern Europe, Russia and Turkey and region 3 
81 patients from Latin America and South Africa. In these last two regions, 
OS was similar for eribulin and TPC; however  sample sizes were substan-
tially smaller than that of region 1, and recruitment started much later. Re-
sults are thus less mature [18]. 
The secondary end point, progression-free survival (PFS), on the other hand, 
did not show favourable results for the eribulin group (I 3.7 months versus C 
2.2 months). In contrast, the objective response rate (ORR; sum of complete 
and partial response) was 12% in the eribulin arm and 5% in the TPC arm 
(p=0.002). 
Haematological, as well as non-haematological side effects of all grades were 
overall more often observed in the eribulin group than in the control group. 
Concerning grade 4 adverse events (AEs), neutropenia was the most com-
mon AE and occurred in 24% in the eribulin group and in 7% in the control 
group; leucopenia in 2% in the eribulin group and in 1% in the TPC group. 
Other grade 4 AEs were uncommon and occurred at maximum in 1%. 5 
deaths related to treatment (i.e. 1%) occurred in the eribulin group due to 
febrile neutropenia, lung infection, and bronchopneumonia and dyspnoea. 2 
patients (i.e. also 1%) died in the TPC group (febrile neutropenia, aspergil-
losis). 
 
study population and 
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eribulin 
control group: various 
chemotherapeutics 
 
 
survival benefit 
 
 
exploratory subset 
analysis 
 
beneficial ORR 
more AEs in the eribulin 
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more neutropenia and 
leucopenia 
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Grade III or IV haematological AEs neutropenia and leucopenia were more 
frequent in the eribulin group compared to TPC: 45% vs. 21% (neutropenia) 
and 14% vs. 6% (leucopenia). While most of the grade III or grade IV non-
haematological AEs were almost equally frequent in both arms (see Table 2), 
peripheral neuropathy was more frequent in the eribulin arm (8% vs. 2%), 
conversely, palmar-plantar erythrodysaesthesia was seen more often in the 
TPC arm. Non-haematological AEs of all grades differed between the two 
groups. Accordingly, asthenia/fatigue, peripheral neuropathy, nausea, dysp-
noea was clearly dominant in the eribulin group. Conversely, only palmar-
plantar erythrodysaesthesia was more common in the TPC group.  
According to the investigators, the outstanding result of the study is the im-
provement in OS of heavily pre-treated BC patients. This result was the base 
for positive approvals in the USA, Europe and other countries. 
6.1 Efficacy and safety - further studies 
Cortes et al. [17] published the results of “Study 211” (a single arm, open la-
bel phase II, multicenter study). The study population consisted of 291 
women with locally advanced or metastatic BC which had been treated pre-
viously with an anthracycline, a taxane and capacitabine. Patients received 
1.4 mg/m2 eribulin at day 1 and 8 of a 21-day cycle. 269 patients were evalu-
able and met the key enrolment criteria [20]. The ORR, the primary end-
point, was 9.3% (95% CI: 6.1% to 13.4%). Median PFS was 2.6 months (0.03 
to 13.1 months), median OS was 10.4 months (range: 0.6 – 19.9) and OS rate 
after 6 months was 72.3%. 
The most common treatment-related AEs of any grade were asthenia/fatigue 
(65%), alopecia (60%), neutropenia (60%), nausea (44%) peripheral neu-
ropathy (33%), and anaemia (28%). While neutropenia was manageable by 
dose delays/reductions or by the application of haematopoietic stimulants, 
peripheral neutropenia (no standard treatment available) was common, but 
less frequent (6.9 % grade III and 0% grade IV), when indirectly compared 
to studies about similar drugs 6 deaths occurred in this study, of which one 
was due to unknown reason and possibly treatment related [20]. QoL pa-
rameters indicated neither a decline nor an improvement among patients 
with tumour response. Patients who responded, showed a decline of pain 
visual analogue scale (VAS) scores. The authors concluded that eribulin has 
antitumor activity in heavily pre-treated patients and that the safety profile 
is manageable and acceptable.  
In “Study 201” (phase II, open label, single arm, multicenter study) [15] 103 
heavily pre-treated (a median of 4 previous treatments) women were as-
signed to eribulin at day 1, 8 and 15 (28-day cycle). Due to frequent neutro-
penia at day 15, a protocol amendment was made, and a second group of pa-
tients received eribulin only at day 1 and 8 of a 21-day cycle. Of 87 patients, 
ORR per-protocol was 11.5%. The median PFS was 2.6 months and the me-
dian OS was 9.0 months. The most common grade III and IV toxicities were 
neutropenia (64%), leucopenia (18%), fatigue (5%), peripheral neuropathy 
(5%), and febrile neutropenia (4%). Two deaths occurred due to neutropenic 
sepsis and thrombocytopenia and were considered as probably related to 
treatment [20]. 
neutropenia and 
leucopenia much more 
frequent in treatment 
with eribulin 
eribulin with more 
peripheral neuropathy 
 
more all grade AE with 
eribulin 
 phase II: 
“Study 211” 
phase II 
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7 Estimated costs 
In Austria, the manufacturer price for one 2ml-vial injectable solution of 
Halaven® containing 0.88 mg (= 0.44mg/ml) is € 400.- [22]. Assuming a 
mean body surface area (BSA) of 1.7m², a dose of 2.1 mg eribulin (1.2g/1 m²) 
should be administered. Therefore, 3 vials are required, resulting in costs of 
€ 1,200.-. Two injections (day 1 and day 8) are needed within one 21-day cy-
cle summing up to € 2,400.- for one cycle. In the eribulin-arm of the EM-
BRACE trial, 503 women of the treatment arm received at least 5 cycles, 
adding up to total costs of about € 12,000.- for a treatment per person. 
Moreover, assuming the average BSA, every administration of eribulin 
would leave a rest of 0.54 mg, corresponding to costs of € 245.-.  Therefore, of 
the total treatment costs, € 2,450.- would be wasted, unless hospitals prepare 
cancer drugs centralised. 
8 Ongoing research 
Two phase III trials with eribulin are planned to be completed in 2011 
(www.clinicaltrials.gov): 
Metastatic Breast Cancer 
 NCT00337103: E7389 (eribulin) Versus Capecitabine in Patients 
With Locally Advanced or Metastatic Breast Cancer Previously 
Treated With Anthracyclines and Taxanes. The primary completion 
date is September 2011. 
This study will be of importance, since the authors of the EMBRACE trial 
announced [8] that study NCT00337103 will also publish QoL data. 
Soft Tissue Sarcoma 
 NCT01327885: Phase III Study to Compare the Efficacy and Safety of 
Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma. 
Primary completion date is August 2011. 
The list of Phase II trials on eribulin that are recorded on www.clinical-
trials.gov shows one study NCT00879086 “Eribulin Mesylate and Ixabepi-
lone” that focuses on neuropathy. The risk of neuropathy is a major consid-
eration in eribulin including treatment decision in advanced cancer. There-
fore, the results of this study are of importance in weighing benefit and 
harm of eribulin. 
Other planned and ongoing studies on eribulin indicate that eribulin is also 
tested for a variety of other cancers such as solid tumours, non-small cell 
lung cancer or prostate cancers. It is also studied for specific subgroups of 
breast cancer (e.g. NCT01269346: HER2 Positive Breast Cancer; 
NCT01268150: HER2 Negative Breast Cancer) and for  
 the early-line setting (NCT01328249: Early Stage Breast Cancer; 
NCT01269346: First-line Therapy; NCT01268150: First-Line Therapy), in-
dicating that the therapeutic use of eribulin could extend in future. 
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9 Commentary 
Patients with metastatic BC have an unmet clinical need for improved ther-
apy in this stage of disease, because there is a lack of effective therapy in this 
setting. Eribulin was recently approved by the EMA and the FDA [3][4], 
mainly based on the results of the EMBRACE trial [18]. The most notewor-
thy result of the EMBRACE study is that, for the first time, improvements 
in OS were found in the late-line setting of metastatic BC.  
Based on the results from the EMBRACE trial the EMA’s Committee of 
Medical Products for Human Use subsumed that the low tolerability of 
eribulin is outweighed by the positive effect on survival, resulting in an 
overall positive benefit risk balance [20]. However, some issues regarding 
the EMBRACE trial should be pointed out. 
Firstly, the therapeutic aim for patients with metastatic BC is, besides pro-
longation of OS, the improvement of QoL. But, data for this outcome are 
still missing, thus hampering a judgement on the balance of benefits and 
harms. Moreover, without knowing if QoL is improved, or at least main-
tained by administering eribulin, the gain of 2.5 months in OS is put into 
perspective. Thus, the question is whether this result represents a clinically 
relevant finding, foremost as a recent survey amongst clinicians and patients 
highlighted the fact that expectations in minimum improvements in OS for 
new therapies differ between these two groups [23]. The majority of physi-
cians (i.e. 48%) considered an incremental improvement in OS of 4–6 
months as meaningful, whereas 46% of patients expected a gain of more 
than 12 months. Even though these gains were expected for first-line thera-
pies of metastatic breast cancer, patient preferences have to be taken into ac-
count, especially within the late-line setting.  
Another issue regarding the effect on survival is that the upper limit of the 
confidence interval is close to 1.0– which indicate that the observed differ-
ence is small (HR = 0.81 ; 95% CI: 0.66 – 0.99). Thus, eventual protocol vio-
lations might have an impact on the conclusion. On the other hand, it 
should be mentioned, that an updated analysis showed at least slightly im-
proved results (HR = 0.81; 95% CI: 0.68 – 0.97) [20]. 
Moreover, the study population comprised women with all kind of breast 
cancers, regardless of their receptor status, a fact which does not reflect cur-
rent practice. Therefore, it is impossible to identify subgroups which might 
benefit the most or might have a higher vulnerability to AEs of eribulin 
therapy. Similarly, no descriptions of AEs in relation to survival or to the 
state of tumour control are provided in the publication. Hence, it remains 
unclear, if patients with a more or less beneficial effect from the therapy 
were more or less affected by AEs.  
One additional point of concern is the adequacy of the therapy in the control 
group. Firstly, it can be questioned why no single control group participant 
received best supportive care only. Secondly, many patients with positive 
HER2 receptors who were not previously treated with trastuzumab had been 
included in the trial and, additionally, no therapy with trastuzumab (that is 
indicated for HER2 positive patients) was applied in the control group. In-
deed, it would be important to know the clinical response if these patients 
were treated with trastuzumab and subsequently to eribulin. Thirdly, no in-
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formation on algorithms or guidelines that grounded the TPC decisions are 
presented.  
Furthermore, in the EMBRACE trial the participants and the investigators 
were not blinded to treatment allocation. In general, blinding is clearly rec-
ommended in controlled trials to increase the methodological robustness.  
Another issue is that different definitions of breast cancer indications for 
eribulin were defined by the FDA and the EMA. According to the EMA, 
eribulin is indicated in progressive cases of “locally advanced and metastatic 
disease”. While the EMA defines “locally advanced and metastatic disease” 
as “breast cancer that has spread beyond the original tumour” [3], it is a 
matter of interpretation, for which particular indications, beyond metastatic 
disease, eribulin is indicated. In comparison, the FDA did not adopt the in-
dication “...locally advanced or metastatic breast cancer...” that was pro-
posed by the applicant. Instead, the indication was limited to metastatic BC, 
because only two cases of locally recurrent breast cancer, and no cases other 
than metastatic cancer were included in the study population of the EM-
BRACE trial [24].  
The costs of eribulin are comparable to other available treatment options. 
However, it is likely that eribulin will soon be used for earlier lines of thera-
pies for BC. Also, trials are under way assessing eribulin for other tumours, 
such as lung cancer or bladder cancer. Therefore, the costs of eribulin might 
eventually add-up.  
Future research should complement the existing evidence on eribulin. On 
the one hand, information regarding QoL and pain relieve is needed, and, on 
the other hand, studies should address direct comparisons of eribulin with 
alternative approaches. Thus, studies that compare eribulin with placebo 
and best supportive care and with other late line therapeutics would be of 
value. Thereby, specific study populations regarding prognostic factors (e.g. 
receptor status) should be defined. 
Resume 
The EMBRACE trial [18] demonstrated a significant improvement in OS for 
eribulin, but also high toxicity. The trial has some methodological weak-
nesses which might undermine the robustness of the results.  In addition, 
against the clinical benefit obtained with eribulin, it should be clarified if 
this important advantage is sufficient and adequate to offset the adverse 
events that were often serious and more frequent. Finally, to date, the lack of 
data on the QoL makes even more difficult the evaluation of the true clinic 
advantage following treatment with eribulin. In 2011, a head-to-head phase 
III trial (eribulin versus capecitabine; NCT00337103) and two phase II stud-
ies (NCT00879086, NCT00965523) are expected to be completed. This new 
evidence will be of great importance to assess the overall balance of benefits 
and harms of eribulin compared with other treatment alternatives. 
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